Global Biosimilars Market by Product, Manufacturing Type and by Disease Analysis & Forecast to 2023 - ResearchAndMarkets.com

Published: Apr 13, 2018

The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%.

Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness, rising incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.

The biosimilars market by product is categorized into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant glycosylated proteins segment is expected to register the highest CAGR during the forecast period. The factors driving the market for glycosylated proteins are the broad therapeutic area of these proteins; presence of biosimilar versions of monoclonal antibodies at lower prices compared to reference products; numerous biologic drugs underclass monoclonal antibody, follitropin, and erythropoietin going off-patent; and numerous products in the pipeline.

By type of manufacturing, the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The contract manufacturing segment is expected to grow at the highest CAGR during the forecast period. CMOs provide cost-saving benefits to companies in terms of facilities, equipment, and labor costs.

Companies Mentioned

  • Amgen
  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • Mylan
  • Pfizer
  • Samsung Biologics
  • Sandoz
  • Stada Arzneimittel AG
  • Teva Pharmaceutical

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Regulatory Outlook

7 Biosimilars Market, By Product

8 Biosimilars Market, By Type of Manufacturing

9 Biosimilars Market, By Disease

10 Biosimilars Market, By Region

11 Competitive Landscape

12 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/b4xjl5/global?w=4

Back to news